• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重的α1-抗胰蛋白酶缺乏症会增加静脉血栓栓塞的风险。

Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism.

机构信息

Department of Respiratory Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.

Department of Clinical Sciences Lund, Respiratory Medicine and Allergology, Faculty of Medicine, Lund University, Lund, Sweden.

出版信息

J Thromb Haemost. 2021 Jun;19(6):1519-1525. doi: 10.1111/jth.15302. Epub 2021 Apr 9.

DOI:10.1111/jth.15302
PMID:33763945
Abstract

BACKGROUND

Severe alpha-1-antitrypsin deficiency (AATD), phenotype PiZZ, is associated with increased risk of liver disease and chronic obstructive pulmonary disease (COPD), but the risk of venous thromboembolism (VTE) is unknown. Our aim was to evaluate the risk of VTE in individuals with severe AATD compared with control subjects from the general population.

METHODS

Individuals with severe AATD (n = 1577) were recruited from the Swedish national AATD register. Control subjects (n = 5969) were selected from the OLIN (Obstructive Lung Disease in Northern Sweden) studies, that include a random general population sample. Longitudinal data on VTE and diagnoses were obtained from the Swedish National Patient Registry. Associations were analyzed using multivariable Cox regression.

RESULTS

At inclusion, 46% of the AATD individuals and 53% of the controls were never-smokers. COPD was present in 46% of the AATD individuals compared with 4% of the controls. During a median follow-up of 18 years, 116 (7%) of the AATD individuals and 89 (1%) of the control subjects developed VTE, unadjusted hazard ratio 6.5 (95% confidence interval 4.9-8.6). Risk factors for incident VTE were male gender, age, COPD, cancer, and liver disease. Adjusting for these factors, the AATD individuals had a significantly higher risk of incident VTE, adjusted hazard ratio 4.2 (95% confidence interval 2.9-6.2) as compared with the controls.

CONCLUSION

Subjects with severe AATD have considerably increased risk of developing VTE compared with the general population, even after accounting for risk factors. This calls for optimized risk factor management and clinical follow-up of this patient group.

摘要

背景

严重的α-1-抗胰蛋白酶缺乏症(AATD),表型 PiZZ,与肝病和慢性阻塞性肺疾病(COPD)的风险增加有关,但静脉血栓栓塞症(VTE)的风险尚不清楚。我们的目的是评估与一般人群中的对照相比,严重 AATD 个体发生 VTE 的风险。

方法

从瑞典国家 AATD 登记处招募了 1577 名严重 AATD 患者。对照(n=5969)从 OLIN(瑞典北部阻塞性肺病)研究中选择,包括随机的一般人群样本。从瑞典国家患者登记处获得关于 VTE 和诊断的纵向数据。使用多变量 Cox 回归分析关联。

结果

在纳入时,46%的 AATD 患者和 53%的对照组从未吸烟。与对照组的 4%相比,46%的 AATD 患者患有 COPD。在中位随访 18 年期间,116(7%)名 AATD 患者和 89(1%)名对照组患者发生 VTE,未调整的危险比为 6.5(95%置信区间 4.9-8.6)。发生 VTE 的危险因素是男性、年龄、COPD、癌症和肝病。在调整这些因素后,与对照组相比,AATD 患者发生 VTE 的风险显著增加,调整后的危险比为 4.2(95%置信区间 2.9-6.2)。

结论

与一般人群相比,严重 AATD 患者发生 VTE 的风险显著增加,即使考虑到危险因素也是如此。这需要优化该患者群体的危险因素管理和临床随访。

相似文献

1
Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism.严重的α1-抗胰蛋白酶缺乏症会增加静脉血栓栓塞的风险。
J Thromb Haemost. 2021 Jun;19(6):1519-1525. doi: 10.1111/jth.15302. Epub 2021 Apr 9.
2
Decreased Risk of Ischemic Heart Disease in Individuals with Severe Alpha 1-Antitrypsin Deficiency (PiZZ) in Comparison with the General Population.严重的α1-抗胰蛋白酶缺乏症(PiZZ)个体患缺血性心脏病的风险低于普通人群。
Int J Chron Obstruct Pulmon Dis. 2020 Jun 4;15:1245-1252. doi: 10.2147/COPD.S247377. eCollection 2020.
3
Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status.氧依赖型慢性阻塞性肺疾病患者的肺移植及生存结局与α-1抗胰蛋白酶缺乏状态的关系。
Int J Chron Obstruct Pulmon Dis. 2017 Nov 7;12:3281-3287. doi: 10.2147/COPD.S148509. eCollection 2017.
4
Decline in FEV and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency.严重的α-1 抗胰蛋白酶缺乏症个体的 FEV 下降和住院加重。
Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1075-1083. doi: 10.2147/COPD.S195847. eCollection 2019.
5
Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42.42 岁重度 α-1-抗胰蛋白酶缺乏症个体的肺功能和健康状况。
Int J Chron Obstruct Pulmon Dis. 2021 Dec 23;16:3477-3485. doi: 10.2147/COPD.S335683. eCollection 2021.
6
Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease.长期氧疗试验中α-1抗胰蛋白酶缺乏个体的特征及其与其他慢性阻塞性肺疾病患者的比较。
Ann Am Thorac Soc. 2015 Dec;12(12):1796-804. doi: 10.1513/AnnalsATS.201506-389OC.
7
Cancer risk in severe alpha-1-antitrypsin deficiency.严重的α-1-抗胰蛋白酶缺乏症的癌症风险。
Eur Respir J. 2022 Oct 27;60(4). doi: 10.1183/13993003.03200-2021. Print 2022 Oct.
8
Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease.α1-抗胰蛋白酶缺乏症和慢性阻塞性肺疾病中肺气肿的独特和共有系统性生物标志物。
EBioMedicine. 2022 Oct;84:104262. doi: 10.1016/j.ebiom.2022.104262. Epub 2022 Sep 22.
9
Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study.基于人群队列研究的罕见和常见 SERPINA1 变异体与血栓形成风险。
J Thromb Haemost. 2022 Jun;20(6):1421-1427. doi: 10.1111/jth.15696. Epub 2022 Mar 19.
10
The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening.通过筛查确定的严重α-1-抗胰蛋白酶缺乏症患者的临床病程。
Int J Chron Obstruct Pulmon Dis. 2022 Jan 5;17:43-52. doi: 10.2147/COPD.S340241. eCollection 2022.

引用本文的文献

1
Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.α-1抗胰蛋白酶缺乏症相关肝病:从研究不足的疾病到基因医学的典型代表。
Hepatol Commun. 2025 Apr 14;9(5). doi: 10.1097/HC9.0000000000000699. eCollection 2025 May 1.
2
Genetic factors, risk prediction and AI application of thrombotic diseases.血栓性疾病的遗传因素、风险预测及人工智能应用
Exp Hematol Oncol. 2024 Aug 27;13(1):89. doi: 10.1186/s40164-024-00555-x.
3
"Super" SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions.
“超级”丝氨酸蛋白酶抑制剂——血栓炎症状态下对抗纤维蛋白溶解的稳定力量。
Front Cardiovasc Med. 2023 Apr 19;10:1146833. doi: 10.3389/fcvm.2023.1146833. eCollection 2023.
4
Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19.α1-抗胰蛋白酶与白细胞介素 6 失衡与 COVID-19 住院期间的死亡率和血栓形成有关。
Biochimie. 2022 Nov;202:206-211. doi: 10.1016/j.biochi.2022.07.012. Epub 2022 Aug 8.
5
Clinical characteristics and risk factors predictive of pulmonary embolism complicated in bronchiectasis patients: a retrospective study.临床特征及预测支气管扩张症合并肺栓塞的危险因素:一项回顾性研究。
BMC Pulm Med. 2022 Jun 9;22(1):225. doi: 10.1186/s12890-022-02016-9.
6
Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.抗凝血丝氨酸蛋白酶抑制剂:止血和血栓形成的内源性调节因子。
Front Cardiovasc Med. 2022 May 3;9:878199. doi: 10.3389/fcvm.2022.878199. eCollection 2022.
7
Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews.与α-1 抗胰蛋白酶缺乏症相关的疾病负担:系统和结构化文献回顾。
Eur Respir Rev. 2022 Mar 23;31(163). doi: 10.1183/16000617.0262-2021. Print 2022 Mar 31.
8
Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study.基于人群队列研究的罕见和常见 SERPINA1 变异体与血栓形成风险。
J Thromb Haemost. 2022 Jun;20(6):1421-1427. doi: 10.1111/jth.15696. Epub 2022 Mar 19.